🔗 Share this article Prestigious Award Recognizes Pioneering Immune System Discoveries The Nobel Prize in Physiology or Medicine was granted for transformative discoveries that illuminate how the body's defense network attacks harmful pathogens while sparing the healthy tissues. A trio of esteemed researchers—from Japan Prof. Sakaguchi and American experts Mary Brunkow and Fred Ramsdell—received this honor. The research identified unique "security guards" within the defense system that eliminate malfunctioning defense cells capable of attacking the body. The findings are now enabling new therapies for immune disorders and malignancies. The winners will share a prize fund worth 11m Swedish kronor. Decisive Findings "Their work has been essential for comprehending how the body's defenses functions and the reason we do not all suffer from severe autoimmune diseases," commented the head of the award panel. This trio's research explain a core mystery: How does the defense system defend us from countless infections while leaving our own tissues intact? Our immune system uses immune cells that scan for signs of infection, including pathogens and bacteria it has not met before. These cells employ sensors—known as receptors—that are generated by chance in countless combinations. That gives the defense network the ability to combat a wide array of threats, but the randomness of the mechanism inevitably produces white blood cells that may attack the body. Security Guards of the Immune System Scientists earlier understood that some of these problematic white blood cells were eliminated in the immune organ—the site where immune cells mature. The latest Nobel Prize honors the identification of regulatory T-cells—described as the immune system's "peacekeepers"—which travel through the system to disarm any defenders that attack the healthy cells. We know that this process fails in autoimmune diseases such as juvenile diabetes, MS, and rheumatoid arthritis. The prize committee stated, "The findings have established a new field of investigation and spurred the creation of new treatments, for example for cancer and immune disorders." Regarding cancer, regulatory T-cells prevent the system from attacking the tumor, so research are aimed at lowering their quantity. In self-attack disorders, trials are testing boosting T-reg cells so the organism is not being harmed. A similar method could also be useful in minimizing the risks of organ transplant failure. Pioneering Studies Prof Shimon Sakaguchi, of Osaka University, performed tests on mice that had their immune gland extracted, leading to autoimmune disease. He showed that introducing defense cells from healthy mice could stop the disease—implying there was a system for preventing defenders from harming the host. Dr. Brunkow, affiliated with the Institute for Systems Biology in Seattle, and Dr. Ramsdell, now at a biotech firm in San Francisco, were studying an genetic autoimmune disease in mice and humans that led to the identification of a gene critical for how regulatory T-cells operate. "Their pioneering work has revealed how the body's defenses is controlled by regulatory T cells, preventing it from accidentally targeting the healthy cells," said a leading biological science expert. "The research is a remarkable illustration of how fundamental biological study can have broad consequences for human health."